Exhibit 99.1 Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments • Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: ◦ Portfolio targeting large indications including obesity, epilepsy, bipolar disorder, depression, obsessive- compulsive disorder (OCD), migraine, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, and cancer. Also ...